Lipoprotein-lipase modifications in subjects treated with a synthetic, heparin-like polyanion (SP 54).
D000284:Administration, Oral; D001161:Arteriosclerosis / Q000517:prevention & control; D001778:Blood Coagulation Disorders / Q000188:drug therapy; D006493:Heparin / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D050356:Lipid Metabolism; D008071:Lipoprotein Lipase / Q000378:metabolism*; D008074:Lipoproteins / Q000378:metabolism; D013923:Thromboembolism / Q000517:prevention & control; D013997:Time Factors
D008074:Lipoproteins; D006493:Heparin; D008071:Lipoprotein Lipase